Lineage Therap (LCTX) Gets a Buy from Craig-Hallum
Albert Lowe from Craig-Hallum reiterated a Buy rating on Lineage Therap with a price target of $3.00. Lowe is a 4-star analyst with an average return of 16.5% and a 50.68% success rate. Lineage Therap also received a Buy rating from H.C. Wainwright’s Joseph Pantginis, while TR reiterated a Hold rating on November 13.
In a report released today, Albert Lowe from Craig-Hallum reiterated a Buy rating on Lineage Therap, with a price target of $3.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
According to TipRanks, Lowe is a 4-star analyst with an average return of 16.5% and a 50.68% success rate. Lowe covers the Healthcare sector, focusing on stocks such as Rezolute, Atossa Therapeutics, and Skye Bioscience.
In addition to Craig-Hallum, Lineage Therap also received a Buy from H.C. Wainwright’s Joseph Pantginis in a report issued yesterday. However, on November 13, TR | OpenAI – 4o reiterated a Hold rating on Lineage Therap (NYSE MKT: LCTX).
